These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 28870253)

  • 21. Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer.
    Hu X; Zhang J; Xu B; Jiang Z; Ragaz J; Tong Z; Zhang Q; Wang X; Feng J; Pang D; Fan M; Li J; Wang B; Wang Z; Zhang Q; Sun S; Liao C
    Int J Cancer; 2014 Oct; 135(8):1961-9. PubMed ID: 24604288
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer.
    Kim JW; Lee KW; Kim KP; Lee JH; Hong YS; Kim JE; Kim SY; Park SR; Nam BH; Cho SH; Chung IJ; Park YS; Oh HS; Lee MA; Kang HJ; Park YI; Song EK; Han HS; Lee KT; Shin DB; Kang JH; Zang DY; Kim JH; Kim TW
    Oncologist; 2017 Mar; 22(3):293-303. PubMed ID: 28209749
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer.
    Zhang BY; Jones JC; Briggler AM; Hubbard JM; Kipp BR; Sargent DJ; Dixon JG; Grothey A
    Clin Colorectal Cancer; 2017 Jun; 16(2):124-128. PubMed ID: 27726953
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 15-PGDH expression as a predictive factor response to neoadjuvant chemotherapy in advanced gastric cancer.
    Hu M; Li K; Maskey N; Xu Z; Peng C; Tian S; Li Y; Yang G
    Int J Clin Exp Pathol; 2015; 8(6):6910-8. PubMed ID: 26261578
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
    Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
    Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma?
    Goldstein D; Rosenberg JE; Figlin RA; Townsend RR; McCann L; Carpenter C; Pandite L
    Eur J Cancer; 2016 Jan; 53():96-104. PubMed ID: 26702763
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab.
    Lee CK; Kim SS; Park S; Kim C; Heo SJ; Lim JS; Kim H; Kim HS; Rha SY; Chung HC; Park S; Jung M
    Oncotarget; 2017 May; 8(19):31169-31179. PubMed ID: 28415714
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical observation of apatinib mesylate for the treatment of multi-drug resistant advanced breast cancer].
    Lü HM; Zhang MW; Niu LM; Zeng HA; Yan M
    Zhonghua Yi Xue Za Zhi; 2018 Apr; 98(16):1246-1249. PubMed ID: 29747313
    [No Abstract]   [Full Text] [Related]  

  • 29. Drug-related adverse events potentially predict the efficacy of apatinib on advanced hepatocellular carcinoma.
    Gu X; Zhang S; Yang X; Guan T; Hou Z; Cao M; Li H; Zhang T
    BMC Gastroenterol; 2022 Oct; 22(1):441. PubMed ID: 36316630
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multicenter phase II study of apatinib treatment for metastatic gastric cancer after failure of second-line chemotherapy.
    Ruan H; Dong J; Zhou X; Xiong J; Wang H; Zhong X; Cao X
    Oncotarget; 2017 Nov; 8(61):104552-104559. PubMed ID: 29262660
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adipose tissue area as a predictor for the efficacy of apatinib in platinum-resistant ovarian cancer: an exploratory imaging biomarker analysis of the AEROC trial.
    Huang X; Xie C; Tang J; He W; Yang F; Tian W; Li J; Yang Q; Shen J; Xia L; Lan C
    BMC Med; 2020 Oct; 18(1):267. PubMed ID: 33012286
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
    Li F; Zhu T; Cao B; Wang J; Liang L
    Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma.
    Rautiola J; Donskov F; Peltola K; Joensuu H; Bono P
    BJU Int; 2016 Jan; 117(1):110-7. PubMed ID: 25252180
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Concurrent apatinib and docetaxel vs apatinib monotherapy as third- or subsequent-line therapy for advanced gastric adenocarcinoma: a retrospective study.
    Lin H; Han D; Fu G; Liu C; Wang L; Han S; Liu B; Yu J
    Onco Targets Ther; 2019; 12():1681-1689. PubMed ID: 30881023
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The combination of apatinib and S-1 for the treatment of advanced gastric cancer in China: A meta-analysis of randomized controlled trials.
    Liu Y; Zhou C; Zhang K; Feng Y; Zhang R
    Medicine (Baltimore); 2018 Nov; 97(47):e13259. PubMed ID: 30461630
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Efficacy and Survival Analysis of Apatinib in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer after Failure of First-line Treatment].
    Wang X; Zhang W; Du W; Zhang X; Ren X; Cao S
    Zhongguo Fei Ai Za Zhi; 2017 Nov; 20(11):761-768. PubMed ID: 29167006
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness and Safety of Apatinib in Patients with Advanced or Metastatic Adenocarcinoma of Stomach or Gastroesophageal Junction: A Prospective Observation Study.
    Shen B; Jiang H; Wang L; Qian J; Shu Y; Chen P; Mao G; Liu B; Zhang X; Liu C; Wu J; Li X; Cai W; Shen W; Wang Q; He J; Hua D; Zhang Z; Zhang Y; Feng J
    Onco Targets Ther; 2020; 13():4457-4464. PubMed ID: 32547076
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Application effect of apatinib in patients with failure of standard treatment for advanced malignant tumours.
    Liu G; Wang C; He Y; E M
    BMC Pharmacol Toxicol; 2019 Oct; 20(1):61. PubMed ID: 31661009
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early Adverse Event Derived Biomarkers in Predicting Clinical Outcomes in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy.
    Chen DT; Saltos AN; Rose T; Thompson ZJ; Thapa R; Chiappori A; Gray JE
    Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173987
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypertension as a predictive biomarker in patients with advanced non-small-cell lung cancer treated with apatinib.
    Fang SC; Huang W; Zhang YM; Zhang HT; Xie WP
    Onco Targets Ther; 2019; 12():985-992. PubMed ID: 30774384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.